Company Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
The company’s clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Rd., Suite F200 Radnor, Pennsylvania 19087 United States | |
| Phone | 888 378 6240 |
| Website | mineralystx.com |
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001933414 |
| CUSIP Number | 603170101 |
| ISIN Number | US6031701013 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jon Congleton | President, Chief Executive Officer and Director |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder and Executive Director |
| Adam Scott Levy | Chief Financial Officer and Secretary |
| Dr. David M. Rodman M.D. | Chief Medical Officer |
| Sarah Foster | Senior Vice President of People |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 144 | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 144 | Filing |
| Jul 30, 2025 | 144 | Filing |
| Jul 28, 2025 | 144 | Filing |
| Jul 14, 2025 | 144 | Filing |
| Jul 11, 2025 | 144 | Filing |
| Jul 11, 2025 | 144 | Filing |
| Jun 17, 2025 | 8-K | Current Report |